These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 17242369)
21. In vitro validation of effects of BDNF-expressing mesenchymal stem cells on neurodegeneration in primary cultured neurons of APP/PS1 mice. Song MS; Learman CR; Ahn KC; Baker GB; Kippe J; Field EM; Dunbar GL Neuroscience; 2015 Oct; 307():37-50. PubMed ID: 26297896 [TBL] [Abstract][Full Text] [Related]
22. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. Rockenstein E; Mante M; Adame A; Crews L; Moessler H; Masliah E Acta Neuropathol; 2007 Mar; 113(3):265-75. PubMed ID: 17131129 [TBL] [Abstract][Full Text] [Related]
23. Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology. Herring A; Ambrée O; Tomm M; Habermann H; Sachser N; Paulus W; Keyvani K Exp Neurol; 2009 Mar; 216(1):184-92. PubMed ID: 19118549 [TBL] [Abstract][Full Text] [Related]
25. Icariin decreases both APP and Aβ levels and increases neurogenesis in the brain of Tg2576 mice. Li F; Dong HX; Gong QH; Wu Q; Jin F; Shi JS Neuroscience; 2015 Sep; 304():29-35. PubMed ID: 26079110 [TBL] [Abstract][Full Text] [Related]
26. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease. Nemirovsky A; Fisher Y; Baron R; Cohen IR; Monsonego A Vaccine; 2011 May; 29(23):4043-50. PubMed ID: 21473952 [TBL] [Abstract][Full Text] [Related]
27. A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model. Zhu L; Yang JY; Xue X; Dong YX; Liu Y; Miao FR; Wang YF; Xue H; Wu CF Mech Ageing Dev; 2015 Sep; 150():34-45. PubMed ID: 26200391 [TBL] [Abstract][Full Text] [Related]
28. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease. Solomon B Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423 [TBL] [Abstract][Full Text] [Related]
29. [Current trend of immunotherapy for Alzheimer's disease]. Matsumoto SE; Tabira T Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765 [TBL] [Abstract][Full Text] [Related]
30. Oligomeric pyroglutamate amyloid-β is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy. Wirths O; Hillmann A; Pradier L; Härtig W; Bayer TA J Alzheimers Dis; 2013; 35(4):741-9. PubMed ID: 23481684 [TBL] [Abstract][Full Text] [Related]
32. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice. Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784 [TBL] [Abstract][Full Text] [Related]
33. Generation of auto-antibodies towards Alzheimer's disease vaccination. Frenkel D; Kariv N; Solomon B Vaccine; 2001 Mar; 19(17-19):2615-9. PubMed ID: 11257400 [TBL] [Abstract][Full Text] [Related]
34. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss. Ager RR; Davis JL; Agazaryan A; Benavente F; Poon WW; LaFerla FM; Blurton-Jones M Hippocampus; 2015 Jul; 25(7):813-26. PubMed ID: 25530343 [TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for Alzheimer's disease. Solomon B; Frenkel D Neuropharmacology; 2010; 59(4-5):303-9. PubMed ID: 20388523 [TBL] [Abstract][Full Text] [Related]
37. Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Hao W; Liu Y; Liu S; Walter S; Grimm MO; Kiliaan AJ; Penke B; Hartmann T; Rübe CE; Menger MD; Fassbender K Brain; 2011 Jan; 134(Pt 1):278-92. PubMed ID: 21115468 [TBL] [Abstract][Full Text] [Related]
38. Early neuronal loss and axonal/presynaptic damage is associated with accelerated amyloid-β accumulation in AβPP/PS1 Alzheimer's disease mice subiculum. Trujillo-Estrada L; Dávila JC; Sánchez-Mejias E; Sánchez-Varo R; Gomez-Arboledas A; Vizuete M; Vitorica J; Gutiérrez A J Alzheimers Dis; 2014; 42(2):521-41. PubMed ID: 24927710 [TBL] [Abstract][Full Text] [Related]
39. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075 [TBL] [Abstract][Full Text] [Related]
40. Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease. Moon M; Hong HS; Nam DW; Baik SH; Song H; Kook SY; Kim YS; Lee J; Mook-Jung I J Alzheimers Dis; 2012; 29(3):615-28. PubMed ID: 22269161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]